UPCC 02419: An Open-label Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285) A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor in Patients with Advanced Systemic Mastocytosis

  • STATUS
    Recruiting
  • participants needed
    5
Send
Updated on 19 February 2024

Summary

This research study is an open-label study designed to learn about the safety and effectiveness of an experimental drug called avapritinib (also known as BLU-285) when given to individuals who have been diagnosed with ASM, SM-AHN, or MCL. Experimental means that it is not yet known if this drug helps patients and is not available for sale. Open label means that you and your study doctor know you will receive avapritinib during the study. ASM, SM-AHN, or MCL (referred to as SM going forward) are disorders where abnormal mast cells accumulate in many organs and in bone marrow and cause abnormal organ function. Mast cells are a type of white blood cell that is part of the immune system. When increased in number or abnormal in function they release their contents resulting in allergic reactions and other related symptoms, which are also associated with mastocytosis.

Details
Condition Advanced Systemic Mastocytosis
Age 99years or below
Clinical Study Identifier03580655
Last Modified on19 February 2024

Eligibility

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.